PURPOSE: To clarify whether changes in the cholinergic transmission occur early in the course of Alzheimer's disease (AD), we carried out positron emission tomography (PET) with the radioligand 2-[(18)F]F-A-85380, which is supposed to be specific for alpha4beta2 nicotinic acetylcholine receptors (nAChRs). METHOD: We included patients with moderate to severe AD and patients with amnestic mild cognitive impairment (MCI), presumed to present preclinical AD. RESULTS: Both patients with AD and MCI showed significant reductions in alpha4beta2 nAChRs in brain regions typically affected by AD pathology. These findings indicate that a reduction in alpha4beta2 nAChRs occurs during early symptomatic stages of AD. The alpha4beta2 nAChR availability in these regions correlated with the severity of cognitive impairment, indicating a stage sensitivity of the alpha4beta2 nAChR status. CONCLUSION: Together, our results provide evidence for the potential of 2-[(18)]F-A-85380 nAChR PET in the diagnosis of patients at risk for AD. Because of the extraordinary long acquisition time with 2-[(18)F]F-A-85380, we developed the new alpha4beta2 nAChR-specific radioligands (+)- and (-)-[(18)F]norchloro-fluoro-homoepibatidine (NCFHEB) and evaluated them preclinically. (-)-[(18)F]NCFHEB shows twofold higher brain uptake and significantly shorter acquisition times. Therefore, (-)-[(18)F]NCFHEB should be a suitable radioligand for larger clinical investigations.
PURPOSE: To clarify whether changes in the cholinergic transmission occur early in the course of Alzheimer's disease (AD), we carried out positron emission tomography (PET) with the radioligand 2-[(18)F]F-A-85380, which is supposed to be specific for alpha4beta2 nicotinic acetylcholine receptors (nAChRs). METHOD: We included patients with moderate to severe AD and patients with amnestic mild cognitive impairment (MCI), presumed to present preclinical AD. RESULTS: Both patients with AD and MCI showed significant reductions in alpha4beta2 nAChRs in brain regions typically affected by AD pathology. These findings indicate that a reduction in alpha4beta2 nAChRs occurs during early symptomatic stages of AD. The alpha4beta2 nAChR availability in these regions correlated with the severity of cognitive impairment, indicating a stage sensitivity of the alpha4beta2 nAChR status. CONCLUSION: Together, our results provide evidence for the potential of 2-[(18)]F-A-85380 nAChR PET in the diagnosis of patients at risk for AD. Because of the extraordinary long acquisition time with 2-[(18)F]F-A-85380, we developed the new alpha4beta2 nAChR-specific radioligands (+)- and (-)-[(18)F]norchloro-fluoro-homoepibatidine (NCFHEB) and evaluated them preclinically. (-)-[(18)F]NCFHEB shows twofold higher brain uptake and significantly shorter acquisition times. Therefore, (-)-[(18)F]NCFHEB should be a suitable radioligand for larger clinical investigations.
Authors: A Nordberg; P Hartvig; A Lilja; M Viitanen; K Amberla; H Lundqvist; J Andersson; H Nybäck; J Ulin; Y Anderson Journal: Acta Radiol Suppl Date: 1991
Authors: J P Sullivan; D Donnelly-Roberts; C A Briggs; D J Anderson; M Gopalakrishnan; M Piattoni-Kaplan; J E Campbell; D G McKenna; E Molinari; A M Hettinger; D S Garvey; J T Wasicak; M W Holladay; M Williams; S P Arneric Journal: Neuropharmacology Date: 1996-06 Impact factor: 5.250
Authors: David D Allen; Paul R Lockman; Karen E Roder; Linda P Dwoskin; Peter A Crooks Journal: J Pharmacol Exp Ther Date: 2003-03 Impact factor: 4.030
Authors: Steven T DeKosky; Milos D Ikonomovic; Scot D Styren; Laurel Beckett; Stephen Wisniewski; David A Bennett; Elizabeth J Cochran; Jeffrey H Kordower; Elliott J Mufson Journal: Ann Neurol Date: 2002-02 Impact factor: 10.422
Authors: A T Hillmer; D W Wooten; J M Moirano; M Slesarev; T E Barnhart; J W Engle; R J Nickles; D Murali; M L Schneider; J Mukherjee; B T Christian Journal: Synapse Date: 2011-08-31 Impact factor: 2.562
Authors: Jennifer M Coughlin; Stephanie Slania; Yong Du; Hailey B Rosenthal; Wojciech G Lesniak; Il Minn; Gwenn S Smith; Robert F Dannals; Hiroto Kuwabara; Dean F Wong; Yuchuan Wang; Andrew G Horti; Martin G Pomper Journal: J Nucl Med Date: 2018-03-01 Impact factor: 10.057